NightHawk Biosciences (NYSE:NHWK) Releases Earnings Results, Beats Estimates By $0.09 EPS

NightHawk Biosciences (NYSE:NHWKGet Rating) announced its earnings results on Monday. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09, MarketWatch Earnings reports. NightHawk Biosciences had a negative net margin of 1,995.52% and a negative return on equity of 29.20%.

Shares of NYSE NHWK traded down $0.18 during trading hours on Thursday, hitting $2.27. The company had a trading volume of 76,170 shares, compared to its average volume of 115,443. NightHawk Biosciences has a 1-year low of $1.60 and a 1-year high of $10.85. The firm’s 50 day moving average is $2.58 and its 200-day moving average is $3.20.

A number of institutional investors and hedge funds have recently bought and sold shares of NHWK. Renaissance Technologies LLC bought a new position in NightHawk Biosciences during the 4th quarter worth $339,000. Dimensional Fund Advisors LP boosted its stake in shares of NightHawk Biosciences by 55.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 78,058 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 27,764 shares in the last quarter. Morgan Stanley boosted its stake in shares of NightHawk Biosciences by 690.8% during the second quarter. Morgan Stanley now owns 66,426 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 58,026 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of NightHawk Biosciences by 12.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 56,465 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 6,278 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in NightHawk Biosciences in the fourth quarter worth approximately $82,000. Institutional investors and hedge funds own 18.12% of the company’s stock.

A number of research firms have weighed in on NHWK. B. Riley decreased their price target on shares of NightHawk Biosciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 18th. StockNews.com initiated coverage on shares of NightHawk Biosciences in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of NightHawk Biosciences in a report on Tuesday, March 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $14.33.

NightHawk Biosciences Company Profile (Get Rating)

Heat Biologics, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

See Also

Earnings History for NightHawk Biosciences (NYSE:NHWK)

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.